720012Renephra LtdClosedGRD Development of PrototypeInnovate UKDialysis is the current mainstream treatment for patients suffering kidney failure. During treatment the quality of life for patients is very poor, treatment in hospital three times a week prevents many patients from working, survival rates are less than 50% at 5 years, and the cost to the state approximates £30k per annum per patient. We have a technology capable of eventually replacing dialysis with a minimally invasive, efficacious and pain-free treatment at a significantly lower cost. Mathematical modelling confirms that the idea is feasible, and preprototype testing was encouraging. We require funding to design and build a prototype device that will then be tested in clinical studies. The project represents a highly proactive approach to a chronic condition. The technology could address a number of key concerns: the ability to eventually safely self-treat at home will dramatically reduce hospital admissions, and daily therapy has been demonstrated to improve the quality of health of renal patients. This therapy will significantly reduce the cost of renal care, which even in many advanced economies has resulted in patients waiting for treatment due to lack of resources. The technology is anticipated to offer a superior alternative to predialysis patients who retain some kidney function, delaying or even removing the need for their entry into a dialysis programme. The device will enable effective solutions to be tailored to patients needs: treatment can be delivered in the home at a time that fits with their lifestyle, and selective toxin capture can be patient specific.